Inflammatory Bowel Disease Competitive Grant Program (United States)

Pfizer, Inc.

Suggest an update

Grant amount: Up to US $150,000

Anticipated deadline: Feb 8, 2020 8:59pm PST

Applicant type: Research Scientist Doctor Postdoctoral Researcher Faculty

Funding uses: Research

Location of project: United States

Location of residency: United States

View website    Save Need help writing this grant?

About this funder:



Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research/quality improvement program.

Inflammatory Bowel Disease Competitive Grant Program

The intent of this Request for Proposal (RFP) is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge of the epidemiology, pathogenesis and treatment of Inflammatory Bowel Disease (IBD).

Areas of Focus

The overall focus of the competitive research grants program is to support both clinical and basic science research on the pathogenesis and treatment of IBD with a specific focus on projects that are most relevant to improving patient care.

All US investigators are encouraged to apply, including young investigators who are in the early stages of their career.

Specific areas of interest include:

  • Use of biomarkers in the assessment, management and identification of IBD and to predict response to treatment and disease course
  • Clinical, proteomic, transcriptomic, and genomic characteristics of TNF naïve vs. TNF IR patients with Ulcerative Colitis (UC)
  • Predictive and prognostic clinical features and response to JAK therapy in IBD
  • Basic research in the etiology of selected autoimmune and inflammatory diseases in gastroenterology
  • Approaches to characterizing gaps in care, delays in care, and adherence to treatment in IBD
  • Approaches to improving management such as: treating to target by monitoring response and adjusting therapy; evidence-based treatment algorithms; factors predictive of response to therapy; evaluation of sequencing of therapy
  • Signaling pathways implicated in the pathogenesis of IBD
  • Research that further elucidates the role and impact of JAK inhibition based on JAK pairings/cytokines/cell types/PK/Doses and other parameters beyond JAK isoform selectivity
  • Thrombotic risk in UC
  • Understanding lipid elevations with regard to the IBD disease state
  • The role of JAK inhibition with extra-intestinal manifestations of UC
  • Research that will further inform the risk of colon and other cancers in patients on UC therapies
  • Evaluation of the increased risk of cardiovascular disease in patients with IBD
  • Exploration of the role of JAK/STAT pathways in pathogenesis of IBD.

Expected Approximate Monetary Range of Grant Applications

  • Individual projects requesting up to $150,000 will be considered.
  • The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification

You can learn more about this opportunity by visiting the funder's website.


  • Geographic Scope: United StatesTo be eligible:
    • The principal investigator (PI) and institution must be based in one of the eligible countries noted above.
    • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
    • Applicant must be affiliated with a host institution